Abstract
By histological analysis, pulmonary vascular remodeling induced by MCT was also inhibited (vessel wall thickness: MCT 0.44 vs. M/A 0.31, p b 0.001). MCT treatment increased mRNA levels of endothelin (ET) receptor-A, ET receptor-B, ET-1 and transforming growth factor (TGF)beta in the lung. ADRCs therapy suppressed these increased mRNA (p b 0.05). Conclusion ADRC therapy inhibited the development of PAH by reversing the changes in ET expression and inflammatory cytokines. These findings suggest that ADRC therapy may open a novel strategy to treat PAH.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
